凱普生物(300639.SZ):簽署7000萬元股票回購貸款合同
格隆匯11月19日丨凱普生物(300639.SZ)公佈,公司與中國銀行股份有限公司潮州分行簽署了《上市公司股票回購/增持業務專項借款合同》。合同主要內容包括:借款金額為7,000萬元,借款期限為12個月,自實際提款日起算;借款用途為專項用於證券代碼300639股票回購。公司將根據市場情況在回購期限內擇機實施本次回購計劃,並按照相關法律法規的規定及時履行信息披露義務。本次簽署股票回購專項貸款合同不構成關聯交易,亦不構成重大資產重組,不會對公司當年的經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.